Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy.
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
28
02
2023
received:
15
11
2022
accepted:
16
03
2023
medline:
9
6
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Nonrandomized studies (NRS) on allergen immunotherapy (AIT) particularly lend themselves to evaluate outcomes that are insufficiently addressed in randomized controlled studies (RCTs). However, NRS are prone to several sources of bias, which limit their validity. We aimed at comparing AIT effects between RCTs and NRS and evaluate the reasons for discrepancies in study results. In this analysis, we compared NRS on AIT (including subcutaneous and sublingual immunotherapy, SCIT and SLIT, respectively) with SLIT and SCIT RCTs from published meta-analyses, assessing the Risk of Bias (RoB) for each study and the certainty of evidence from NRS and RCTs using the GRADE approach. We found: (1) very serious RoB in the 7 NRS included in the meta-analysis showing a large difference between AIT and controls (standardized mean difference [SMD] for symptom score [SS], -1.77; 95% CI, -2.30, -1.24; p < .001; I
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
610-625Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic Rhinoconjunctivitis: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(8):1301-1309.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Di Lorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol. 2012;130(5):1097-1107.e2.
Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010;2010(12):CD002893. doi:10.1002/14651858.CD002893.pub2
Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;2007(1):CD001936. doi:10.1002/14651858.CD001936.pub2
Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131:1361-1366.
Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72(12):1825-1848. doi:10.1111/all.13208
Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy. 2017;72(3):342-365. doi:10.1111/all.13077. Erratum in: Allergy. 2017 Oct;72 (10):1590.
Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691-704.
Di Lorenzo G, Leto-Barone MS, La Piana S, Plaia A, Di Bona D. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. Int Forum Allergy Rhinol. 2017;7(7):660-669.
Schünemann HJ, Tugwell P, Reeves BC, et al. Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions. Res Synth Methods. 2013;4(1):49-62.
Paoletti G, Di Bona D, Chu DK, et al. Allergen immunotherapy: the growing role of observational and randomized trial “real-world evidence”. Allergy. 2021;76(9):2663-2672.
Ioannidis JP, Haidich AB, Pappa M, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286(7):821-830. doi:10.1001/jama.286.7.821
Eichler HG, Abadie E, Breckenridge A, et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response. Nat Rev Drug Discov. 2011;10:495-506. doi:10.1038/nrd3501
Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014;2014(4):MR000034. doi:10.1002/14651858.MR000034.pub2
Sterne JAC, Hernán MA, McAleenan A, Reeves BC, Higgins JPT. Chapter 25: assessing risk of bias in a non-randomized study. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated February 2021). Cochrane; 2021. www.training.cochrane.org/handbook
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
Di Bona D, Paoletti G, Chu DK, et al. Allergen immunotherapy for respiratory allergy: quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis. Clin Transl Allergy. 2021;11(4):e12033.
Kim JY, Jang MJ, Kim DY, Park SW, Han DH. Efficacy of subcutaneous and sublingual immunotherapy for house dust mite allergy: a network meta-analysis-based comparison. J Allergy Clin Immunol Pract. 2021;9(12):4450-4458. doi:10.1016/j.jaip.2021.08.018
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.
The GRADE Working Group. GRADE Handbook. 2013. Accessed June 20, 2022.guidelinedevelopment.org/handbook
Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, et al., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane; 2022.
GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime. 2021. Accessed March 15, 2022. gradepro.org
Eng PA, Borer-Reinhold M, Heijnen IAFM. Gnehm HPE twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy. 2006;61:198-201.
Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dustmite: a 10-year prospective study. Clin Exp Allergy. 2003;33:206-210.
Acquistapace F, Agostinis F, Castella V, et al. Efficacy of sublingual specific immunotherapy in intermittent and persistent allergic rhinitis in children: an observational case-control study on 171 patients. The EFESO-children multicenter trial. Pediatr Allergy Immunol. 2009;20:660-664.
De Castro G, Zicari AM, Indinnimeo L, et al. Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children's real life. Eur Rev Med Pharmacol Sci. 2013;17(16):2225-2231.
Djuric-Filipovic I, Caminati M, Filipovic D, Salvottini C, Zivkovic Z. Effects of specific allergen immunotherapy on biological markers and clinical parameters in asthmatic children: a controlled-real life study. Clin Mol Allergy. 2017;15:7.
Arena A, Barbatano E, Gammeri E, Bruno M, Riva G. Specific immunotheraphy of allergic diseases: a three years perspective observational study. Int J Immunopathol Pharmacol. 2003;16(3):277-282.
Giovannini M, Braccioni F, Sella G, et al. Comparison of allergen immunotherapy and drug treatment in seasonal rhinoconjunctivitis: a 3-years study. Eur Ann Allergy Clin Immunol. 2005;37(2):69-71.
Marogna M, Bruno M, Massolo A, Falagiani P. Long-lasting effects of sublingual immunotherapy for house dust mites in allergic rhinitis with bronchial hyperreactivity: a long-term (13-year) retrospective study in real life. Int Arch Allergy Immunol. 2007;142(1):70-78.
Marogna M, Bruno ME, Massolo A, Falagiani P. Sublingual immunotherapy for allergic respiratory disease in elderly patients: a retrospective study. Eur Ann Allergy Clin Immunol. 2008;40(1):22-29.
Milani M, Pecora S, Burastero S. EFESO investigators study group: observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin. 2008;24(9):2719-2724.
Dominicus R. 3-years' long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Eur Ann Allergy Clin Immunol. 2012;44:135-140.
Droessaert V, Timmermans M, Dekimpe E, et al. Real-life study showing better control of allergic rhinitis by immunotherapy than regular pharmacotherapy. Rhinology. 2016;54(3):214-220.
Bożek A, Krupa-Borek I, Jarzab J. Twenty years' observation of subcutaneous pollen allergoid immunotherapy efficacy in adults. Postepy Dermatol Alergol. 2017;34(6):561-565.
Rhyou H-I, Nam Y-H. Efficacy of allergen immunotherapy for allergic asthma in real world practice. Allergy Asthma Immunol Res. 2020;12(1):99-109.
Klimek L, Uhlig J, Mösges R, Rettig K, Pfaar O. A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy. 2014;69(12):1629-1638.
Kiel MA, Röder E, van Gerth Wijk R, Al MJ, Hop WC, Rutten-van Mölken MP. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132(2):353-360.
Egert-Schmidt AM, Kolbe JM, Mussler S, Thum-Oltmer S. Patients' compliance with different administration routes for allergen immunotherapy in Germany. Patient Prefer Adherence. 2014;24(8):1475-1481.
Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol. 2010;126(3):668-669.
Roche N, Campbell JD, Krishnan JA, et al. Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force. Clin Transl Allergy. 2019;27(9):20.
Minozzi S, Cinquini M, Gianola S, Castellini G, Gerardi C, Banzi R. Risk of bias in nonrandomized studies of interventions showed low inter-rater reliability and challenges in its application. J Clin Epidemiol. 2019;112:28-35.